Monday, 28 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Earnings Call

Lupin Earnings Call: Key Takeaways

Lupin reported record FY26 revenues of ₹27,958 cr (up 23%) and EBITDA of ₹8,160 cr (up 55%). Management focuses on complex products and India prescription growth.

Why this was an Alfa AlertPrimary metric beat: Guided EBITDA margin 27-28%, achieved 29.7%, a 6% beat above upper guidance (170bps). Management confirmed 'handsomely beat' guidance.
Highlights
Revenue growth23% YoY for FY26.
MarginsFY26 29.7%; FY27 expected lower at 25% due to competition.
Demand visibilityStrong for chronic therapies and new biosimilars.
Management confidenceHigh for India and complex US launches.

Growth

FY26 Revenue grew 23% YoY; US business up 40% to $1.318bn; India prescription business grew 10.6%.

Outlook

FY27 Guidance: high single-digit revenue growth with ~25% EBITDA margins. Plans to launch 50+ US products in 3 years.

Risks

Potential price erosion in Tolvaptan/Mirabegron; US competition; inflationary freight costs; geopolitical uncertainty.

Source

Earnings Call filed with NSE, NSE: LUPIN. Summary written with AI assistance from the document.

Read the document ↗

Lupin Ltd: key numbers

Share price
₹2,092.00
Market cap
₹95,665 Cr
Revenue (annual)
₹27,958 Cr
Net profit (annual)
₹5,333 Cr
P/E (TTM)
17.3×Sector 50.4×
Promoter holding
46.85%-0.01% QoQ
FII holding
22.42%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Lupin Ltd

All →
16:14 IST BSE
Employee Stock Options

Lupin Employee Stock Options

Lupin Ltd allotted 24,111 equity shares to employees following the exercise of vested stock options under the company's ESOP schemes.

17:38 IST NSE
Product Launch

Lupin Product Launch

Lupin received US FDA approval for Modafinil Tablets, USP, a generic version of Provigil. This regulatory approval enables the company to market the drug in the U.S.